Alkem Laboratories Q4 FY26 Results: Earnings Expectations

Alkem Laboratories Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Alkem Laboratories was listed on the National Stock Exchange (NSE) on 23-Dec-2015. Alkem Laboratories share has its face value of 2 per share, and its NSE symbol is ALKEM. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Alkem Laboratories Q4 Results 2026 Preview

• Alkem Laboratories Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 11-15% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 12-17% YoY.
• EBITDA to rise 13.50%.
• Alkem Laboratories is expected to show Moderate Growth Expected in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

Alkem Laboratories Share Performance

• Over the past six months, Alkem Laboratories share price has 22% by 11-16% to 5,567.50.
• Moreover, over the past year, the stock has 38% by Up
• Despite this weak short-term performance, Alkem Laboratories stock has delivered a financially sound 190% return over the past 5 years.
• As of today, 10-03-2026, the Alkem Laboratories share price is trading at 5,567.50 per share.

Key Factors to Watch for Alkem Laboratories Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Alkem Laboratories

Alkem Laboratories is a leading Indian pharmaceutical company specializing in the development, manufacturing, and marketing of generic and branded medicines. Its portfolio includes anti-infectives, gastrointestinal, and chronic therapies, serving both domestic and international markets.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Alkem Laboratories is gear up to announce its Q4 FY26 results. Analysts expect 11-15% revenue growth, a 12-17% rise in PAT, and a 13.50% rise in EBITDA. Alkem Laboratories focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Alkem Laboratories Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Adani Green Energy Q4 FY26 Results Preview: Renewable Energy Momentum

Adani Enterprises Q4 FY26 Earnings Preview: What to Expect

ACE Q4 FY26 Earnings Preview: Infra and Equipment Demand

Accelya Solutions Q4 FY26 Results Preview: Aviation Tech Demand

Abbott India Q4 FY26 Earnings Preview: Healthcare Growth Outlook